Process for the optical purification of the single enantiomers of some 2-sulphinyl-1H-benzimidazole derivatives and another structurally related sulphoxide from the respective enantiomerically enriched preparation thereof.

An enteric coated oral pharmaceutical formulation comprising as active ingredient a compound selected from the group of omeprazole, an alkaline salt of omeprazole, the (-)-enantiomer of omeprazole and an alkaline salt of the (-)-enantiomer of omeprazole, wherein the formulation comprises a core material of the active ingredient and optionally an alkaline reacting compound, the active ingredient is in admixture with a pharmaceutically acceptable excipient, such as for instance a binding agent, an...

The present invention relates to a novel process for the synthesis of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl] sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. Moreover, the present invention also relates to manufacture of a pharmaceutical preparation thereof and its use in medicine. The novel process for the preparation of omeprazole, comprises the step of oxidizing 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole in an organic ...

FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to pharmaceutical preparation of omeprazole. Pharmaceutical preparation covered by enterosoluble envelope as an active component comprises compound taken among group consisting of omeprazole, omeprazole alkaline salt, (-)- enantiomer omeprazole and (-)-enantiomer omeprazole alkaline salt. This preparation comprises core comprising an active component and, possibly, alkaline reagent being an active component is in the mixture w...

The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to ...

The invention provides S-omeprazole in a neutral form characterised in that it is in a solid state, preferably in a partly crystalline or substantially crystalline state, such as form A or form B. Furthermore, the invention provides processes for the preparation of S-omeprazole and its use in medicine.

The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of th...